Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SL 279252

Next Previous
Drug Profile

SL 279252

Alternative Names: PD1-Fc-OX40L; SL-279252; TAK-252

Latest Information Update: 13 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shattuck Labs
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytokine stimulants; Immunologic cytotoxicity; OX40 receptor agonists; Programmed cell death 1 ligand 2 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Solid tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lymphoma; Solid tumours

Most Recent Events

  • 23 Feb 2023 Discontinued - Phase-I for Lymphoma (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Spain, Belgium, USA, Canada (IV)
  • 23 Feb 2023 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Belgium, Spain, USA, Canada (IV)
  • 11 Aug 2022 SL 279252 is still in phase-I trials for Lymphoma in USA, Belgium and Spain (NCT03894618)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top